Toward a Safer Blood Supply: The Impact of Molecular Testing

  • Niel T. Constantine
  • Patricia A. Wright
  • Ahmed Saleh
  • Anna DeMarinis
Chapter
Part of the Molecular and Translational Medicine book series (MOLEMED)

Abstract

Blood banks in the USA strive to have the safest blood supply in the world. To accomplish this, testing for infectious diseases is federally mandated through strict regulatory measures and is continuously monitored for effectiveness and accuracy. Extraordinary quality assurance oversight is omnipresent and monitored by several government and nongovernmental organizations including the Food and Drug Administration (FDA), American Association of Blood Banks (AABB), and various state health authorities.

Keywords

Fatigue Hepatitis Albumin Agar Europe 

References

  1. 1.
    Facts about the blood supply. http://www.redcrossblood.org/learn-about-blood/blood-facts-and-statistics. Retrieved 27 July 2012.
  2. 2.
    Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion. 2002;42(5):537–48.PubMedCrossRefGoogle Scholar
  3. 3.
    Constantine NT, Saville RD, Dax EM. Retroviral testing and quality assurance: essentials for laboratory diagnosis. Ann Arbor, MI: Malloy Printers; 2005.Google Scholar
  4. 4.
    Branson BM, McDougal JS. Establishing the diagnosis of HIV infection. In: Dolin R, Masur H, Saag M, editors. AIDS therapy. 3rd ed. Philadelphia, PA: Churchill-Livingstone and Elsevier Inc.; 2008. p. 1–22.Google Scholar
  5. 5.
    Barletta JM, Edelman DC, Constantine NT. Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen. Am J Clin Pathol. 2004;122:20–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Barletta J, Bartolome A, Constantine NT. Immunomagnetic quantitative immuno-PCR for detection of less than one HIV-1 virion. J Virol Methods. 2009;157:122–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Wainberg MA, Brenner BG. The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs. Mol Biol Int. 2012;2012:256982.PubMedGoogle Scholar
  8. 8.
    Alter HJ, Klein HG. The hazards of blood Transfusion in historical perspective. Blood. 2008;112(7): 2617–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Rao MR, Abdollah B, Naficy AB, Darwish MA, Darwis NM, Schisterman E, Clemens JD, Edelman R. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis. 2002;2:29–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Chou R, Clark E, Helfand M. Screening for hepatitis C virus infection [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US); 2004. Systematic Evidence Reviews, No. 24. http://www.ncbi.nlm.nih.gov/books/NBK43248/.Google Scholar
  11. 11.
    Ribeiro MA, Martins ML, Teixeira C, Ladeira R, de Fátima OM, Januário JN, Proietti FA, Carneiro-Proietti AB. Blocking vertical transmission of human T-cell lymphotropic virus type 1 and 2 through breastfeeding interruption. Pediatr Infect Dis J. 2012;31(11):1139–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Blood safety: reducing the risk of transfusion-transmitted infections. http://www.unboundmedicine.com/redbook/ub/view/RedBook/187182/3/blood_safety:_reducing_the_risk_of_transfusion_transmitted_infections. Accessed 4 Aug 2012.
  13. 13.
    Roback JD, Combs MR, Grossman BJ, Hillyer CD, editors. Technical manual. 16th ed. Bethesda, MD: American Association of Blood Banks; 2008.Google Scholar
  14. 14.
    Rassi Jr A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010 April 17;375(9723):1388–402. Review.Google Scholar
  15. 15.
    Young C, Losikoff P, Chawla A, Glasser L, Forman E. Transfusion-acquired Trypanosoma cruzi infection. Transfusion. 2007 Mar;47(3):540–4.Google Scholar
  16. 16.
    Mascola L, Kubak B, Radhakrishna S, Mone T, Huntere R, Leiby DA, Kuehnert M, Moore A, Steurer F, Lawrence G, Kun H. Chagas disease after organ transplantation – Los Angeles, CA, 2006. MMWR Morb Mortal Wkly Rep. 2006;55:798–800.Google Scholar
  17. 17.
    Kun H, Moore A, Mascola L, Steurer F, Lawrence G, Kubak B, Radhakrishna S, Leiby D, Herron R, Mone T, Hunter R, Kuehnert M. Chagas disease in transplant recipients investigation team. Clin Infect Dis. 2009 Jun 1;48(11):1534–40.Google Scholar
  18. 18.
    Teizeira AR, Hecht MM, Guimaro MC, Sousa AO, Nitz N. Pathogenesis of chagas’ disease: parasite persistence and autoimmunity. Clin Microbiol Rev. 2011 Jul;24(3):592–630. Review.Google Scholar
  19. 19.
    Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009 Sep 1;49(5):52–4.Google Scholar
  20. 20.
    Galavíz-Silva L, Molina-Garza DP, González-Santos MA, Mercado-Hernández R, González-Galavíz JR, Rosales-Encina JL, Molina-Garza ZJ. Update on seroprevalence of anti-Trypanosoma cruzi antibodies among blood donors in northeast Mexico. Am J Trop Med Hyg. 2009 Sep;81(3):404–6.Google Scholar
  21. 21.
    Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA. 1965;191:541.PubMedCrossRefGoogle Scholar
  22. 22.
    MMWR. Public health service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence. MMWR Recomm Rep. 1991;40(RR-4):1–17.Google Scholar
  23. 23.
    Zou S, Notari EP, Musavi F, Dodd RY, ARCNET Study Group. Current impact of the confidential unit exclusion option. Transfusion. 2004 May;44(5):651–7.Google Scholar
  24. 24.
    Stramer S. Current risks of transfusion-transmitted agents – a review. Arch Pathol Lab Med. 2007;131:702–7.PubMedGoogle Scholar
  25. 25.
    Zou S, Dorsey K, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer S. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010;50:1495–504.PubMedCrossRefGoogle Scholar
  26. 26.
    Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med. 2011;364:236–47.PubMedCrossRefGoogle Scholar
  27. 27.
    Stramer SL, Zou S, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? Transfusion. 2012;52:440–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Infectious disease testing. http://www.redcrossblood.org/hospitals/infectious-disease-testing Accessed 26 July 2012.
  29. 29.
    Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:6058–68.PubMedCrossRefGoogle Scholar
  30. 30.
    Kaidarova Z, Murphy EL. HTLV-I and –II seroprevalence among United States blood donors, 2000–2009. Retrovirology. 2011;8 suppl 1:A74.CrossRefGoogle Scholar
  31. 31.
    Montgomery S, Brown J, Kushneri M, Smith TL, Crall N, Lanciotti S, Macedo de Oliveira A, Boo T, Marfin AA, 2003 West Nile Virus Transfusion-associated Transmission Investigation Team. Transfusion-associated transmission of West Nile Virus, United States 2003 through 2005. Transfusion. 2006;46(12):2038–46.PubMedCrossRefGoogle Scholar
  32. 32.
    Custer B, Agapova M, Bruhn R, Cusick R, Kamel H, Tomasulo P, Biswas H, Tobler L, Lee TH, Caglioti S, Busch M. Epidemiologic and laboratory findings from 3 years of testing United States blood donors for Trypanosoma cruzi. Transfusion. 2012;52(9):1901–11.PubMedCrossRefGoogle Scholar
  33. 33.
    Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL. Chagas disease and the US blood supply. Curr Opin Infect Dis. 2008 Oct;21(5):476–82.Google Scholar
  34. 34.
    Rosenberg E, Brennan C, Claessens C, Constantine N, Murphy G, Owen S, Werner B, Yao J, Yen-Lieberman B, Branson B, Garrett P, Howell R. Criteria for laboratory testing and diagnosis of HIV infection. CLSI, M53-P, 30(21), ISBN: 1-56238-735-9, 2011.Google Scholar
  35. 35.
    Hare, CB, Pappalardo, BL, Busch MP, Phelps B, Alexander SS, Ramstead C, Levy JA, Hecht, FM. Negative antibody test results among individuals treated with antiretroviral therapy (ART) during acute/early infection. International AIDS Society Meeting, Bangkok, Thailand, 11–16 July, 2004. Poster MoPeB3107.Google Scholar
  36. 36.
    Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871.PubMedCrossRefGoogle Scholar
  37. 37.
    Lindback S, Thorstensson R, Karlsson AC, et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. AIDS. 2000;14:2333.PubMedCrossRefGoogle Scholar
  38. 38.
    Petersen LR, Satten GA, Dodd R, Busch M, Kleinman S, Grindon A, Lenes B. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group. Transfusion. 1994 Apr;34(4):283–9.Google Scholar
  39. 39.
    Lu SN, Tung HD, Chen TM, Lee CM, Wang JH, Hung CH, Chen CH, Changchien CS. Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion? J Viral Hepat. 2004 Nov;11(6):563–70.Google Scholar
  40. 40.
  41. 41.
    Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY. West Nile Virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005;353:451–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Busch MP, Caglioti S, Robertson EF, McAuley JD, Tobler LH, Kamel H, Linnen JM, Shyamala V, Tomasulo P, Kleinman SH. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med. 2005;353:460–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Kleinman SH, Williams JD, Robertson G, Caglioti S, Williams RC, Spizman R, Morgan L, Tomasulo P, Busch MP. West Nile virus testing experience in 2007: evaluation of different criteria for triggering individual-donation nucleic acid testing. Transfusion. 2009;49:1160–70.PubMedCrossRefGoogle Scholar
  44. 44.
    Francis RO, Strauss D, Williams JD, Whaley S, Shaz BH. West Nile Virus infection in blood donors in the New York City area during the 2010 seasonal epidemic. Transfusion. 2012;52(12):2664–70. doi: 10.1111/j.1537-2995.2012.03639.x.PubMedCrossRefGoogle Scholar
  45. 45.
  46. 46.
  47. 47.
  48. 48.
  49. 49.
  50. 50.
    Engel M. Making the blood supply safe also makes it more expensive. Los Angeles Times. 2007. Retrieved 27 July 2012. http://articles.latimes.com/2007/sep/02/local/me-bloodside2.
  51. 51.
    Rauber C, Robertson K. Rising price of blood puts squeeze on hospitals. San Francisco Business Times. 2007. Retrieved 27 Mar 2012. http://www.bizjournals.com/sanfrancisco/stories/2007/01/29/story14.html.
  52. 52.
    Toner RW, Pizzi L, Leas B, Ballas SK, Quigley A, Goldfarb NI. Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services. Appl Health Econ Health Policy. 2011;9(1):29–37.PubMedCrossRefGoogle Scholar
  53. 53.
    Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. April 2010;50:753–65.Google Scholar
  54. 54.
    Custer B. The cost of blood: did you pay too much or did you get a good deal? Transfusion. April 2010;50:742–4.Google Scholar
  55. 55.
    Testimony on FDA’s regulation of blood, blood products, and plasma by Michael A. Friedman, M.D., FDA Lead Deputy Commissioner, before the House Committee on Government Reform and Oversight, Subcommittee on Human Resources and Intergovernmental Relations, June 5, 1997. http://www.hhs.gov/asl/testify/t970605a.html.
  56. 56.
    American Association of Blood Banks. Standards for blood banks and transfusion services. 27th ed. Bethesda, MD: AABB; 2011.Google Scholar
  57. 57.
    Roback JD, editor. Technical manual. 17th ed. Bethesda, MD: AABB; 2011.Google Scholar
  58. 58.
    Constantine NT, Zhao RY. Molecular-based laboratory testing and monitoring for human immunodeficiency virus infections. Clin Lab Sci. 2005;18(4):263–70.PubMedGoogle Scholar
  59. 59.
    Sanjai Kumar, Academy of Science meeting, ref: Nature Med., 19, 2011.Google Scholar
  60. 60.
    Landro L. New threats to U.S. blood supply. http://online.wsj.com/article/SB10001424052748704792104575264600619273586.html. Accessed 31 July 2012.
  61. 61.
    Stramer S. Reported at meeting of Academy of Science, ref-Nature Med, 17, 2011.Google Scholar
  62. 62.
    Keeping the U.S. blood supply safe. p. 14–16. http://www.mlo-online.com/features/2010_july/0710_10.pdf.

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Niel T. Constantine
    • 1
  • Patricia A. Wright
    • 2
  • Ahmed Saleh
    • 1
    • 3
  • Anna DeMarinis
    • 4
  1. 1.Department of Pathology and Institute of Human VirologyUniversity of Maryland School of MedicineBaltimoreUSA
  2. 2.Signature Healthcare-Brockton HospitalBrocktonUSA
  3. 3.Faculty of Science, Zoology DepartmentCairo UniversityCairoEgypt
  4. 4.The DeMarinis Group, LLCNorth AttleboroughUSA

Personalised recommendations